Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with amp, 8-Br-AMP, and rolipram

Journal of Molecular Biology

Volumn 337, Issue 2, 2004, Pages 355-365

  Xu, Robert X ^a   Rocque, Warren J ^a   Lambert, Millard H ^a   Vanderwall, Dana E ^a   Luther, Michael A ^a   Nolte, Robert T ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

8 Br AMP; AMP; CAMP, cyclic 3 ,5 adenosine monophosphate; CGMP, cyclic 3 ,5 gunosine monophosphate; ME2, metal ion 2; PDE; PDE, cyclic nucleotide phosphodiesterase; Rolipram; Structure

Indexed keywords

8 BROMO CYCLIC GMP; ADENOSINE PHOSPHATE; METAL ION; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVB; ROLIPRAM; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CATALYST; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME MECHANISM; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; METAL BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN TARGETING; X RAY ANALYSIS;

EID: 1442323778     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.01.040     Document Type: Article

References (36)

1. Conti M., Jin S.L.C. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucl. Acid Res. Mol. Biol. 63:1999;1-38.
2. Houslay M.D., Sullivan M., Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Advan. Pharmacol. 44:1998;225-342.
3. Manganiello V.C., Murata T., Taira M., Belfrage P., Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch. Biochem. Biophys. 322:1995;1-13.
4. Torphy T.J. Phosphodiesterase inhibitors. Asthma. 2:1997;1755-1773.
5. Zhao A.Z., Yan C., Sonnenburg W.K., Beavo J.A. Recent advances in the study of Ca2+/Cam-activated phosphodiesterases. Signal Transduct Health Dis. 31:1997;237-251.
6. Loughney K., Snyder P.B., Uher L., Rosman G.J., Ferguson K., Florio V.A. Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene. 234:1999;109-117.
7. Fujishige K., Kotera J., Omori K. Striatum- and testis-specific phosphodiesterase PDE10A: isolation and characterization of a rat PDE10A. Eur. J. Biochem. 266:1999;1118-1127.
8. Fawcett L., Baxendale R., Stacey P., McGrouther C., Harrow I., Soderling S., et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc. Natl Acad. Sci. USA. 97:2000;3702-3707.
9. Houslay M.D., Milligan G. Tailoring cAMP-signaling responses through isoform multiplicity. Trends Biochem. Sci. 22:1997;217-224.
10. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:1995;725-748.
11. Weishaar R.E., Cain M.H., Bristol J.A. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. 28:1985;537-545.
12. Conti M., Jin S.L., Monaco L., Repaske R.D., Swinnen J.V. Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocr. Rev. 12:1991;218-234.
13. Teixeira M.M., Gristwood R.W., Cooper N., Hellewell P.G. Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. 18:1997;164-170.
14. Rocque W.J., Tian G., Wiseman J.S., Holmes W.D., Zajac-Thompson I., Willard D.H., et al. Human recombinant phosphodiesterase 4B2B binds (R) -rolipram at a single site with two affinities. Biochemistry. 36:1997;14250-14261.
15. Xu R.X., Hassell A.M., Vanderwall D., Lambert M.H., Holmes W.D., Luther M.A., et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science. 288:2000;1822-1825.
16. Lee M.E., Markowitz J., Lee J.-O., Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex. FEBS Letters. 530:2002;53-58.
17. Huai Q., Wang H., Sun Y., Kim H.-Y., Liu Y., Ke H. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure. 11:2003;865-873.
18. Huai Q., Colicelli J., Ke H. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry. 42:2003;13220-13226.
19. Sung B.-J., Hwang K.-Y., Jeon Y.H., Lee J.I., Heo Y.-S., Kim J.H., et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 425:2003;98-102.
20. Omburo G.A., Jacobitz S., Torphy T.J., Colman R.W. Critical role of conserved histidine pairs HNXXH and HDXXH in recombinant human phosphodiesterase 4A. Cell. Signal. 10:1998;491-497.
21. Lipscomb W.N., Strater N. Recent advances in zinc enzymology. Chem. Rev. 96:1996;2375-2433.
22. Wilcox D.E. Binuclear metallohydrolases. Chem. Rev. 96:1996;2435-2458.
23. Thoden J.B., Phillips G.N., Neal T.M., Raushel F.M., Holden H.M. Molecular structure of dihydroorotase: a paradigm for catalysis through the use of a binuclear metal center. Biochemistry. 40:2001;6989-6997.
24. Zhan C.-G., Zheng F. First computational evidence for a catalytic bridging hydroxide ion in a phosphodiesterase active site. J. Am. Chem. Soc. 123:2001;2835-2838.
25. Muneyama K., Bauer R.J., Shuman D.A., Robins R.K., Simon L.N. Chemical synthesis and biological activity of 8-substituted adenosine 3′,5′-cyclic monophosphate derivatives. Biochemistry. 10:1971;2390-2395.
26. Harris D.N., Chasin M., Phillips M.B., Goldenberg H., Samaniego S., Hess S.M. Effect of cyclic nucleotides on activity of cyclic 3′,5′- adenosine monophosphate phosphodiesterase. Biochem. Pharmacol. 22:1973;221-228.
27. Jin S.L.C., Swinnen J.V., Conti M. Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. J. Biol. Chem. 267:1992;18929-18939.
28. Pillai R., Kytle K., Reyes A., Colicelli J. Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase. Proc. Natl Acad. Sci. USA. 90:1993;11970-11974.
29. Jacobitz S., Ryan M.D., McLaughlin M.M., Livi G.P., DeWolf W.E., Torphy T.J. Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A. Mol. Pharmacol. 51:1997;999-1006.
30. Atienza J.M., Susanto D., Huang C., McCarty A.S., Colicelli J. Identification of inhibitor specificity determinants in a mammalian phosphodiesterase. J. Biol. Chem. 274:1999;4839-4847.
31. Richter W., Unciuleac L., Hermsdorf T., Kronbach T., Dettmer D. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4. Cell. Signal. 13:2001;287-297.
32. Rocque W.J., Holmes W.D., Patel I.R., Dougherty R.W., Ittoop O., Overton L., et al. Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding. Protein Expr. Purif. 9:1997;191-202.
33. Sambrook J., Fritsch E.F., Maniatis T.A. Molecular Cloning: A Laboratory Manual. 2nd edit. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
34. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
35. Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D. 50:1994;760-776.
36. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallog. sect. D. 54:1998;905-921.